AstraZeneca (AZN) has released an update.
AstraZeneca’s new drug Voydeya has been approved by the FDA as an add-on therapy for adults with paroxysmal nocturnal haemoglobinuria (PNH), to treat extravascular haemolysis (EVH). This approval is based on the positive results of the ALPHA Phase III trial, which demonstrated Voydeya’s effectiveness in improving hemoglobin levels and reducing the need for blood transfusions. Voydeya is notable for being a first-in-class oral Factor D inhibitor and has also received Orphan Drug Designation in multiple regions.
For further insights into AZN stock, check out TipRanks’ Stock Analysis page.
